Zacks Investment Research upgraded shares of ASLAN PHARMACEU/ADR (NASDAQ:ASLN) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, Zacks.com reports. They currently have $3.50 target price on the stock.
According to Zacks, “ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company’s product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore. “
Separately, HC Wainwright restated a buy rating on shares of Zomedica Pharmaceuticals in a research note on Wednesday, June 5th.
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last issued its earnings results on Monday, April 29th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $2.70 million. As a group, analysts forecast that ASLAN PHARMACEU/ADR will post -0.73 earnings per share for the current year.
ASLAN PHARMACEU/ADR Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
Featured Story: Beta
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.